Please ensure Javascript is enabled for purposes of website accessibility

Why Acadia Pharmaceuticals Stock Slumped in April

By George Budwell – May 8, 2019 at 3:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The contentious drug-pricing debate weighed on Acadia Pharmaceuticals' shares last month.

What happened

Acadia Pharmaceuticals (ACAD 1.36%), a mid-cap biopharma, saw its shares decline by 10.8% last month, according to data from S&P Global Market Intelligence. What provoked this double-digit sell-off?

Acadia's shares fell victim to the politically charged drug-pricing debate in the United States. While biopharma stocks in general struggled in April because of this hot-button issue, Acadia's shares were hit particularly hard because the company has aggressively raised the price of its Parkinson's disease psychosis medication, Nuplazid, since its launch in May 2016.  

A businessman staring at a downward pointing red arrow that has broken through the floor.

Image Source: Getty Images.

So what

Acadia has hiked Nuplazid's wholesale acquisition cost at about twice the annual rate of inflation in the U.S. over the past three years. That's not an unusual pricing policy for a fairly new branded medication, but it could draw the ire of key political leaders -- especially as the presidential election campaign kicks into high gear later this year.

Acadia, for its part, has needed to take regular price increases on Nuplazid because script numbers haven't quite lived up to expectations, and the company's rising clinical costs have kept it deep in the red. And with Acadia advancing Nuplazid in multiple trials at once and the company picking up another late-stage asset recently, this trend is likely to continue for the foreseeable future. 

Now what

The next major event for Acadia's shares is the upcoming top-line readout for Nuplazid's schizophrenia adjunctive studies. If successful, this indication could add some much-needed juice to Nuplazid's commercial momentum heading into the next decade.

The flip side, though, is that the market has clearly built a massive premium into Acadia's shares based on the assumption that Nuplazid would eventually expand into more-lucrative indications. So these upcoming trial readouts may not provide much of a lift. The company's shares, after all, are already trading at a stately price-to-sales ratio of 15.7, which is well above the average for its peer group. 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
ACAD
$16.36 (1.36%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.